Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873754 | 0.94 | TSHR (0.50) | TSHRLMNAALDH1A1HSD17B10CFTR | |
| SCHEMBL1513963 | 0.87 | TSHR (0.53) | TSHRLMNAALDH1A1HSD17B10KMT2A | |
| SCHEMBL10591636 | 0.84 | TSHR (0.52) | TSHRLMNAALDH1A1HSD17B10KDM4E | |
| SCHEMBL28699777 | 0.83 | TSHR (0.70) | TSHRLMNAALDH1A1HSD17B10KDM4E | |
| SCHEMBL1513969 | 0.81 | ALDH1A1 (0.56) | TSHRLMNAALDH1A1HSD17B10KMT2A | |
| SCHEMBL27637585 | 0.78 | SMN1; SMN2 (0.48) | TSHRLMNAALDH1A1HSD17B10KMT2A | |
| SCHEMBL27583153 | 0.78 | UTS2R (0.48) | TSHRLMNAALDH1A1HSD17B10KMT2A | |
| SCHEMBL28362466 | 0.78 | LMNA (0.55) | TSHRLMNAALDH1A1HSD17B10KMT2A | |
| Ether SCHEMBL4958226 | 0.77 | ALDH1A1 (0.56) | TSHRLMNAALDH1A1HSD17B10KMT2A | |
| SCHEMBL3110030 | 0.76 | ALDH1A1 (0.60) | TSHRALDH1A1HSD17B10CFTRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101453990-B | Bupropion controllable release formulations and manufacturing process thereof | BIOKEY INC | 2015-05-13 | — | — | CN | claimed |
| CN-103945832-A | A composition, device and method for delayed and sustained release of brain energy molecules | JACKS HEALTH TECHNOLOGIES LLC | 2014-07-23 | — | — | CN | claimed |
| US-20230338371-A1 | PHARMACEUTICAL COMPOSITIONS OF PROTAC COMPOUNDS AND USES THEREOF | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023179777-A1 | PHARMACEUTICAL COMPOSITIONS OF PROTAC COMPOUNDS AND USES THEREOF | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023179774-A1 | AMORPHOUS SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-09-28 | — | — | WO | disclosed |
| US-9387190-B2 | Sustained release of topical anesthetics | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150297550-A1 | SUSTAINED RELEASE OF TOPICAL ANESTHETICS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2914258-A1 | SUSTAINED RELEASE OF TOPICAL ANESTHETICS | University Of Kentucky Research Foundation (US) | 2015-09-09 | — | — | EP | disclosed |
| CN-103945832-A | A composition, device and method for delayed and sustained release of brain energy molecules | JACKS HEALTH TECHNOLOGIES LLC | 2014-07-23 | — | — | CN | disclosed |
| WO-2014071203-A1 | SUSTAINED RELEASE OF TOPICAL ANESTHETICS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-1501521-B1 | LONG ACTING COMPOSITIONS COMPRISING ZIDOVUDINE AND/OR LAMIVUDINE | LUPIN LTD (IN) | 2007-05-02 | — | — | EP | disclosed |
| US-6462030-B1 | MICROBIOCIDES TO MYCOPLASMA HOMINIS, MYCOPLASMA CAPRICOLUM, MOBILUNCUS CURTISII AND PREVOTELLA CORPORIS | NEW YORK BLOOD CENTER, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020127276-A1 | Biodegradable microbicidal vaginal barrier device | NEW YORK BLOOD CENTER, INC. | 2002-09-12 | — | — | US | disclosed |
| US-20020076430-A1 | Biodegradable microbicidal vaginal barrier device | NEW YORK BLOOD CENTER, INC. | 2002-06-20 | — | — | US | disclosed |
| WO-2002036055-A1 | BIODEGRADABLE MICROBICIDAL VAGINAL BARRIER DEVICE | NEW YORK BLOOD CENTER, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001005377-A1 | METHOD FOR INACTIVATING BACTERIA ASSOCIATED WITH BACTERIAL VAGINOSIS USING CELLULOSE ACETATE PHTHALATE AND/OR HYDROXYPROPYL METHYLCELLULOSE PHTHALATE | NEW YORK BLOOD CENTER, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| US-6165493-A | \"Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections\ | NEW YORK BLOOD CENTER, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1030547-A1 | METHODS FOR PREVENTING AND TREATING BACTERIAL INFECTIONS USING CELLULOSE ACETATE PHTHALATE OR HYDROXYPROPYL METHYLCELLULOSE PHTHALATE EXCIPIENTS | New York Blood Center, Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| US-5985313-A | Method for decreasing the frequency of transmission of viral infections using cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate excipients | NEW YORK BLOOD CENTER, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999020098-A1 | METHODS FOR PREVENTING AND TREATING BACTERIAL INFECTIONS USING CELLULOSE ACETATE PHTHALATE OR HYDROXYPROPYL METHYLCELLULOSE PHTHALATE EXCIPIENTS | NEW YORK BLOOD CENTER, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338371-A1 | PHARMACEUTICAL COMPOSITIONS OF PROTAC COMPOUNDS AND USES THEREOF | ADRM1, PSMC1, UBE3C | TSHR 3812/4885LMNA 1165/4885ALDH1A1 4530/4885 |
| US-20020127276-A1 | Biodegradable microbicidal vaginal barrier device | MIF, MGAM, HPD | TSHR 4881/4885LMNA 3868/4885ALDH1A1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.